EPICS: Global Perspectives in SCLC (Region 1)

Latest therapeutic developments in SCLC treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?

June 29, 2022


Carl M. Gay, MD, PhD

MD Anderson Cancer Center, Houston, TX, USA

Faculty Members

Apar Kishor Ganti, MD
University of Nebraska Medical Center, Omaha, NE, USA

Jyoti Malhotra, MD, MPH
City of Hope, Duarte, CA, USA

Alberto Chiappori, MD
Moffitt Cancer Center, Tampa, FL, USA

Nagla Abdel Karim, MD
Augusta University, St, Augusta, GA, USA

Anne Chiang, MD, PhD
Yale School of Medicine, New Haven, CT, USA

Joshua K. Sabari, MD
NYU Grossman School of Medicine, New York, NY, USA

Sample Report

Start discovering the insights

View Report


  • Standards of Care Across the SCLC Treatment Continuum
  • Biomarkers in SCLC
  • Recent Progress and Emerging Therapies in Second Line and Beyond

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.